More GE HealthCare details announced, including its potential launch date and first board of directors

GE HealthCare, the upcoming standalone healthcare business from GE, has announced its new board of directors and the target spinoff date.

The spinoff, which was announced in July, is part of GE’s larger plan to spin off three, independent companies––GE HealthCare, GE Vernova and GE Aerospace. The company expects the spinoff of GE HealthCare to be completed the first week of January 2023. 

The first board of directors for GE HealthCare includes H. Lawrence Culp, Jr., Chairman and CEO, GE, and CEO, GE Aerospace, who will serve as non-executive chairman of GE HealthCare. Peter Arduini, CEO of GE HealthCare, will also serve as a director. GE also plans to appoint eight additional directors:

  • Peter J. Arduini, who will also serve as GE Healthcare’s president and CEO
  • H. Lawrence Culp, Jr., who has has served as the chairman and CEO of GE since October 2018
  • Rodney F. Hochman, MD, president and CEO of Providence, a Catholic not-for-profit health system, since 2016
  • Lloyd W. Howell, Jr., CFO and treasurer of Booz Allen Hamilton Holding Company (“Booz Allen”)
  • Risa Lavizzo-Mourey, MD, 
  • Catherine Lesjak
  • Anne T. Madden
  • Tomislav Mihaljevic, MD
  • William J. Stromberg
  • Phoebe L. Yang

“With this initial group of Directors, we have a highly qualified and capable Board that will enable GE HealthCare to hit the ground running,” Culp said in a statement. “The team is building significant momentum and targeting a spin-off during the first week of January, and having our Board in place represents a critical milestone on this path.” 

GE HealthCare manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for medical imaging.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.